Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Set 'Responsible' Price For Kymriah, Express Scripts Says

Executive Summary

Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.

Advertisement

Related Content

PBM Controls Coming To Medical Benefit Drugs? Express Scripts Acquisition Offers Platform
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel